ALK and non-small cell lung carcinoma: Crizotinib significantly prolonged PFS and was superior to cytotoxic chemotherapy in chemonaïve advanced ALK-rearranged NSCLC (PFS: crizotinib 10.9 m versus chemotherapy 7.0 m, HR: 0.45 (95% CI 0.35–0.6), p < 0.0001) and has been considered as standard chemotherapy [177].